Bimatoprost implant demonstrates extended IOP lowering duration of IOP

Some patients treated with the bimatoprost implant demonstrated a sustained IOP lowering and requires no IOP-lowering treatment for ≥2 years after their last administration in a phase 3 trial, according to a study presented at ARVO 2021.

Biodegradable, intracameral bimatoprost implant slowly releases bimatoprost for 3 to 4 months to lower IOP. This analysis evaluated the duration of IOP control provided by the implant in a 24-month, ongoing, open-label, multicenter, long-term safety and efficacy extension study that optionally enrolled patients with open-angle glaucoma or ocular hypertension after their completion of a bimatoprost implant phase 3 clinical trial. The study included patients who had received 10- or 15-µg bimatoprost implant in the study eye on Day 1 and Weeks 16 and 32 in a 20-month, randomized, phase 3 ARTEMIS trial. The analysis evaluated IOP and the number of patients who received no additional (rescue) IOP-lowering treatment in the study eye for ≥2 years after the last implant administration during the ARTEMIS trial.

Among 181 implant-treated patients who completed ARTEMIS and enrolled in the study extension, 48 had not been rescued at the study extension screening, and 32 did not require rescue for ≥2 years after their last implant administration. For these 32, mean (±SD) time without rescue after the last implant administration was 2.6 ± 0.5 years, and mean (±SD) IOP was 23.4 ± 1.9 mm Hg at initial (ARTEMIS study) baseline and 18.1 ± 3.1 mm Hg at the last recorded visit (still without rescue). Seven patients remained untreated for ≥3 years; their mean (±SD) IOP was 22.8 ± 1.5 mm Hg at baseline and 18.0 ± 4.1 mm Hg at the last recorded visit (still without rescue).

Reference
Medeiros FA, et al. Extended duration of IOP lowering with bimatoprost implant in a phase 3 open-label extension study. Presented at: ARVO 2021.